The BMAL1 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 769-P human clear cell renal cell carcinoma (ccRCC) epithelial cell line, designed for targeted disruption of the BMAL1 (ARNTL) gene. This product provides a heterogeneous pool of edited cells, each carrying CRISPR/Cas9-mediated gene disruptions, without single-cell cloning or biallelic knockout selection, enabling robust population-level analyses of loss-of-function phenotypes. The knockout model is well-suited for investigating the multifaceted roles of BMAL1 in circadian biology and cancer signaling, offering a genetically defined tool for advanced research applications.
The parental 769-P cell line was originally established from a primary clear cell adenocarcinoma of the kidney and has been widely adopted as an in vitro model for renal cell carcinoma research. These adherent epithelial cells retain key features of ccRCC pathogenesis, including dysregulated hypoxic signaling due to frequent VHL inactivation, making them particularly relevant for studying the interplay between circadian disruption and renal tumor biology. The 769-P background thus provides a clinically pertinent host for interrogating BMAL1 function in a cancer-autonomous context.
BMAL1 encodes a core circadian clock transcription factor that heterodimerizes with CLOCK to bind E-box regulatory elements, driving rhythmic expression of downstream targets such as PER1, PER2, CRY1, and CRY2, which in turn feed back to inhibit BMAL1-CLOCK activity, forming an autoregulatory transcriptional loop. Beyond the core oscillator, BMAL1 regulates a broad network of clock-controlled genes, including DBP, REV-ERB??, and ROR??, while also intersecting with key cancer-related pathways: it modulates HIF1?? signaling through direct transcriptional regulation and protein interactions, influences mTOR and AMPK-mediated metabolic sensing, and integrates with p53-dependent cell cycle control. BMAL1 activity is governed by multiple upstream regulators, including light/dark cycles, feeding/fasting rhythms, glucocorticoids, and temperature cycles, as well as by hypoxia via HIF1?? and metabolic cues through mTOR and AMPK. Its interacting partners??such as CLOCK, CRY1, PER1/2, SIRT1, HDAC3, and HIF1????further fine-tune its transcriptional output, with direct implications for the expression of metabolic genes (GLUT4, FASN), angiogenic factors (VEGF), and proliferation regulators (c-MYC, PAI-1).
In the context of 769-P ccRCC cells, CRISPR/Cas9-mediated BMAL1 knockout disrupts circadian transcriptional programs, leading to constitutive dysregulation of clock-controlled pathways. This perturbation is anticipated to alter HIF1??-mediated hypoxic responses??already dysregulated in VHL-deficient renal cancer??potentially modifying cellular adaptation to metabolic stress, proliferation rates, and invasive behavior. Given the established cross-talk between the circadian oscillator and oncogenic signaling in clear cell renal carcinoma, the BMAL1 knockout polyclonal cell population serves as a pertinent model system to dissect how loss of circadian rhythm integrity impacts tumor cell biology, including cell cycle progression, metabolic rewiring, and hypoxia-driven gene expression.
Researchers can employ these polyclonal knockout cells in a wide array of experimental assays to explore clock-cancer interactions. Circadian reporter systems (e.g., Bmal1-luciferase) can quantify rhythm disruption, while RT-qPCR profiling of PER2 and DBP expression validates downstream clock gene dysregulation. Western blotting for BMAL1 and HIF1?? proteins, combined with ChIP-qPCR to assess BMAL1 occupancy at E-box sites, directly probes transcriptional mechanisms. Functional studies may include cell proliferation and clonogenic survival assays, flow cytometry for cell cycle distribution, and RNA-seq to capture global circadian transcriptome remodeling. In vivo xenograft tumor growth studies further extend the model to preclinical drug chronotherapy investigations and metabolic studies. For further details or technical support, please contact Ascent Research.
